French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
复制标题
DOI：
10.1183/13993003.02095-2018
复制
发表时间：
2019-05-01
影响因子：
24.3
通讯作者：
Simonneau, Gerald
中科院分区：
文献类型：
--
作者：
Brenot, Philippe;Jais, Xavier;Simonneau, Gerald
目的：评价球囊肺血管成形术（BPA）在大型慢性血栓栓塞性肺动脉高压（CTEPH）患者队列中的安全性和有效性。方法：从2014年到2017年，184名无法手术的CTEPH患者接受了1006次BPA治疗。比较前21个月（初始阶段）与后21个月（近期阶段）的安全性和有效性。共有154例患者在中位持续时间6.1个月后接受了全面评价。结果如下：总体而言，纽约心脏协会功能分级、6分钟步行距离（平均变化+45 m）显著改善，平均肺动脉压（PAP）和肺血管阻力（PVR）分别显著降低26%和43%。平均PAP和PVR的下降百分比在初始阶段分别为22%和37%，而在最近阶段分别为30%和49%（p
Aims: To evaluate safety and efficacy of balloon pulmonary angioplasty (BPA) in a large cohort of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods: From 2014 to 2017, 184 inoperable CTEPH patients underwent 1006 BPA sessions. Safety and efficacy during the first 21 months (initial period) were compared with those of the last 21 months (recent period). A total of 154 patients had a full evaluation after a median duration of 6.1 months. Results: Overall, there was a significant improvement in New York Heart Association functional class, 6-min walk distance (mean change + 45 m), and a significant decrease in mean pulmonary artery pressure (PAP) and in pulmonary vascular resistance (PVR) by 26% and 43%, respectively. The percentage decreases of mean PAP and PVR were 22% and 37% in the initial period versus 30% and 49% in the recent period, respectively (p